Regen BioPharma Inc
OTC:RGBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (22.2), the stock would be worth $-0.05 (12 791% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.2 | $0 |
0%
|
| Industry Average | 22.2 | $-0.05 |
-12 791%
|
| Country Average | 21.9 | $-0.05 |
-12 578%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Regen BioPharma Inc
OTC:RGBP
|
84.9k USD | -0.2 | -0 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
285.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | -38 725.3 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.2B ZAR | 15.5 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.9B USD | -88 198.6 | 38 368.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
59.7B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.4B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 69.7 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.5B USD | 45.4 | -3 256.9 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.7B ZAR | 4.9 | 6.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Regen BioPharma Inc
Glance View
Regen Biopharma, Inc. is a biotechnology company, which focuses on the immunology and immunotherapy space. The company is headquartered in La Mesa, California and currently employs 1 full-time employees. The company went IPO on 2014-09-03. The firm is focused on immuno-oncology, stem cell/cancer stem cell, and gene silencing. The company is engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The firm focuses on the treatment of hematopoiesis (blood formation), breast cancer, liver cancer, leukemia, myelodysplastic syndrome, and aplastic anemia. The firm is also engaged in developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating molecular processes in cancer stem cell through its molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
